Pharmaceutical specialties currently approved enhance antitumor immunity by reversing tumor escape caused by two negative regulators: cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). The gene discussed is PDCD1; the disease is neoplasm.